Promacta — Medica

Initial criteria

• According to the prescriber, patient has poor graft function
• Patient has a platelet count < 50 x 10^9/L (< 50,000/mcL)
• Medication is prescribed by or in consultation with a hematologist, oncologist, or stem cell transplant specialist

Reauthorization criteria

• According to the prescriber, patient demonstrated a beneficial clinical response (e.g., increased or maintained platelet counts, or decreased frequency of bleeding episodes)

Approval duration

6 months initial and reauthorization